Journal of
eISSN: 2373-4345
Submit manuscript...
Editorial Volume 4 Issue 6
Botulinum toxin as an adjunctive in treatment of TMJ ankylosis: step no 10
Ayman Hegab
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
Verify Captcha
Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.
Clinical Associate Professor of Oral & Maxillofacial Surgery, Al-Azhar University, Egypt
Correspondence: Ayman Hegab, Clinical Associate Professor of Oral & Maxillofacial Surgery, Faculty of Dental Medicine, Al-Azhar University, Cairo, Egypt, Tel 00974 33310124, Fax 201000000000
Received: July 13, 2016 | Published: July 29, 2016
Citation: Hegab A. Botulinum toxin as an adjunctive in treatment of TMJ ankylosis: step No 10. J Dent Health Oral Disord Ther. 2016;4(6):154-155. DOI: 10.15406/jdhodt.2016.04.00130
Editorial
The treatment of TMJ Ankylosis is very challenging, not only in achieving adequate facial aesthetics and oral rehabilitation, but also in preventing re-ankylosis. One of the most important extra-articular factors of TMJ re-ankylosis is the activity of the masticatory muscles. Following condylar injury, mandibular movements are restricted due to pain. The restriction of the mandibular movements is brought about by the activity of elevator muscles of the mandible, which may act like a biologic splint. The masticatory muscles in these conditions adapt to a restricted range of mouth opening by shortening. Thus, these muscles could become an additional, extra-articular cause of mandibular movement restriction. These effects are generally more evident when joint pathology exists for a longer period.1 Two different pathologic changes could be associated with the prolonged TMJ ankylosis which includes Degenerative changes or hypertrophy.
It is a well-established phenomenon that skeletal muscles undergo disuse atrophy when they are not in use.2 In TMJ Ankylosis, where the mandible is in a chronic state of closure, the logical inference would thus be that the elevator muscles would undergo degenerative changes or disuse atrophy. It has been suggested that prolonged TMJ ankylosis inhibits the normal use of the joint, are associated with degenerative changes in the masseter, medial pterygoid and temporalis muscles inducing reflex muscle splinting to protect the joint.1
While; Vinay et al evaluates thickness and cross-sectional areas of jaw elevator muscles and indicates that muscle hyperactivity might be associated with ankylosis. A probable hypothesis would be that regular mandibular movements are more difficult to perform due to the stiffness in the joint, which subsequently resulted in increased thickness of the muscles due to the increased functional demand. It could also be that the increased muscle thickness is due to shortening of the muscle, because the height and length of the affected mandibles are smaller than normal.3 Recently; a protocol for management of TMJ ankylosis consisted of nine steps based on the Pathogenesis of Ankylosis and Re-Ankylosis have been published.
The protocol consisted of the following steps:
- Perioperative indomethacin for 2 weeks;
- The creation of a minimal gap of 5 to 10 mm;
- Ipsilateral coronoidectomy and (if required) contra lateral coronoidectomy;
- Pterygomasseteric sling and temporalis muscle release;
- Interpositional dermis fat graft fixed to the condylar stump;
- Insertion of a suction drain;
- Immediate aggressive physiotherapy for at least 6 months;
- Regular long-term follow-up;
- Delayed reconstruction using distraction osteogenesis.1
Botulinum toxin type A (BTA) are purified substances that derived from clostridium botulinum, and can block muscular nerve signals. Injection of very small amounts of BTA into specific facial muscles can block the muscle’s impulse and temporarily weakens the contraction of muscles by blocking the presynaptic cholinergic nerve endings, thus causing relaxation of the voluntary muscle.4 Therefore, it will results in reducing the activity of elevator muscles of the mandible. It has been shown clinically that injection of Botulinum toxin, as an adjunct to surgical therapy, in the masseter muscles of patients operated for TMJ Ankylosis has improved outcomes.5 Based on this concept, I would like to add the preoperative injection of Botulinum toxin in the masseter muscles, as an adjunct pre-operative step to the surgical protocol to surgical therapy, to improve the outcomes.
Funding
None.
Acknowledgments
None.
Conflicts of interest
The author declares there are no conflicts of interest.
References
- Hegab AF. Outcome of Surgical Protocol for Treatment of Temporomandibular Joint Ankylosis Based on the Pathogenesis of Ankylosis and Re-Ankylosis. A Prospective Clinical Study of 14 Patients. J Oral Maxillofac Surg. 2015;73(12):2300–2311.
- Chinnery PF. Muscle Diseases. In: Goldman L, et al., editors. Cecil Medicine. 24th ed. Philadelphia, USA: Saunders Elsevier; 2011. 429–436 p.
- Kumar VV, Malik NA, Visscher CM, et al. Comparative evaluation of thickness of jaw closing muscles in patients with long-standing bilateral temporomandibular joint ankylosis: a retrospective case-controlled study. Clin Oral Investg. 2014;19(2):421–427.
- To EW, Ahuja AT, Ho WS, et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Brit J Plastic Surg. 2001;54(3):197–200.
- Robiony M. Intramuscular Injection of botulinum toxin as an adjunct to total joint replacement in temporomandibular joint ankylosis: preliminary reports. J Oral Maxillofac Surg. 2011;69(1):280–284.
©2016 Hegab. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.